RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

ReShape Lifesciences P/S 2024

ReShape Lifesciences P/S

0.11

ReShape Lifesciences Dividend yield

Ticker

RSLS

ISIN

US7611236032

As of May 28, 2024, ReShape Lifesciences's P/S ratio stood at 0.11, a -93.41% change from the 1.67 P/S ratio recorded in the previous year.

The ReShape Lifesciences P/S history

ReShape Lifesciences Aktienanalyse

What does ReShape Lifesciences do?

ReShape Lifesciences Inc is a medical company that was founded in 2018 and is headquartered in San Clemente, California. The company is involved in the development and marketing of medical devices for the treatment of obesity and metabolic disorders. The company's business model focuses on innovative medical devices and services for the treatment of obesity and metabolic disorders. The company's main goal is to help patients improve their weight and health in a non-surgical way. The company offers not only medical devices but also services such as physician consulting, training for medical professionals, and patient support. The company's core products include the ReShape Vest, a non-invasive weight loss therapy approach, and the ReShape Duo System, a secondary gastric balloon system used in combination with a dietary program to support weight reduction. The company also offers the ReShape Care Plan, a comprehensive program for patients with obesity that is managed by a multidisciplinary team. The program includes individual sessions with a certified dietitian and a behavioral coach to motivate patients through concrete guidance for weight reduction. ReShape Lifesciences is dedicated to research and development of medical devices and services that help patients in weight reduction and improving their health. The company aims to create an affordable, safe, and effective treatment for obesity patients in an innovative manner that aligns with healthcare reform. ReShape Lifesciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding ReShape Lifesciences's P/S Ratio

ReShape Lifesciences's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing ReShape Lifesciences's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating ReShape Lifesciences's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in ReShape Lifesciences’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about ReShape Lifesciences Stock

What is the price-to-earnings ratio of ReShape Lifesciences?

The price-earnings ratio of ReShape Lifesciences is currently 0.11.

How has the price-earnings ratio of ReShape Lifesciences changed compared to last year?

The price-to-earnings ratio of ReShape Lifesciences has increased by -93.41% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of ReShape Lifesciences high compared to other companies?

Yes, the price-to-earnings ratio of ReShape Lifesciences is high compared to other companies.

How does an increase in the price-earnings ratio of ReShape Lifesciences affect the company?

An increase in the price-earnings ratio of ReShape Lifesciences would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of ReShape Lifesciences affect the company?

A decrease in the price-earnings ratio of ReShape Lifesciences would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of ReShape Lifesciences?

Some factors that influence the price-earnings ratio of ReShape Lifesciences are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does ReShape Lifesciences pay?

Over the past 12 months, ReShape Lifesciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ReShape Lifesciences is expected to pay a dividend of 0 USD.

What is the dividend yield of ReShape Lifesciences?

The current dividend yield of ReShape Lifesciences is .

When does ReShape Lifesciences pay dividends?

ReShape Lifesciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ReShape Lifesciences?

ReShape Lifesciences paid dividends every year for the past 0 years.

What is the dividend of ReShape Lifesciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ReShape Lifesciences located?

ReShape Lifesciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von ReShape Lifesciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ReShape Lifesciences from 5/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/28/2024.

When did ReShape Lifesciences pay the last dividend?

The last dividend was paid out on 5/28/2024.

What was the dividend of ReShape Lifesciences in the year 2023?

In the year 2023, ReShape Lifesciences distributed 0 USD as dividends.

In which currency does ReShape Lifesciences pay out the dividend?

The dividends of ReShape Lifesciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von ReShape Lifesciences

Our stock analysis for ReShape Lifesciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ReShape Lifesciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.